Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
Status:
Completed
Trial end date:
2022-01-25
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, parallel-controlled phase I trial comparing the
safety, pharmacokinetics and efficacy of 9MW0813 and aflibercept (EYLEA®) after a single dose
in patients with diabetic macular edema (DME).